England’s drug approval body has resisted pressure from pharmaceutical companies to loosen its process for recommending drugs and is pressing instead for the NHS to speed up the rollout of approved ...

Positive results from the DESTINY-Breast11 Phase III trial revealed that ENHERTU® (fam-trastuzumab deruxtecan-nxki), when ...

Top decision-makers from across the biopharma ecosystem will convene in Chicago for the 2nd BioCentury Grand Rounds – U.S., at the intersection of research, investment and drug development. Designed ...